The regulation of insulin-like growth factor binding protein (IGFBP)-4 proteolytic degradation by insulin-like growth factors (IGFs) has been largely studied in vitro, but not in vivo. The aim of this study was to investigate the involvement of IGFs, IGFBP-2, IGFBP-3, and IGFBP-3 proteolytic fragments in the regulation of IGFBP-4 proteolytic activity in ovine ovarian follicles. Follicular fluid from preovulatory follicles contains proteolytic activity degrading exogenous IGFBP-4. The addition of an excess of IGF-I enhanced IGFBP-4 proteolytic degradation, whereas addition of IGFBP-2 or -3 or monoclonal antibodies against IGF-I and -II dose dependently inhibited IGFBP-4 proteolytic degradation. IGF-I and IGF-II, but not LongR3-IGF-I, reversed this inhibition in a dose-dependent manner. C-terminal, but not N-terminal, proteolytic fragments derived from IGFBP-3 (aa 161-264), as well as heparin-binding domain-containing peptides derived from the C-terminal domain of IGFBP-3 and -5 also induced the inhibition of IGFBP-4 proteolytic degradation. Other heparin-binding domain-containing peptides derived from the connective tissue growth factor (CTGF) and from proteins not related to IGFBP, heparan/heparin interacting protein (HIP) and vitronectin, but not from p36 subunit of annexin II tetramer, inhibited IGFBP-4 degradation. Furthermore, IGFBP-3, mutated on its heparin-binding domain, was not able to inhibit IGFBP-4 proteolytic degradation. So, in ovine preovulatory follicles, IGFBP-4 proteolytic degradation both 1) depends on IGFs, and 2) is inhibited by IGFBP-3 via its C-terminal heparin-binding domain as well as by heparin-binding domain containing peptides. These data suggest that in early atretic follicles, the increase in IGFBP-2 participates in the decrease in IGFBP-4 degradation. In late atretic follicles, the increase in the levels of C-terminal IGFBP-3 proteolytic fragments, generated by IGFBP-3 degradation, as well as the increase in IGFBP-5 expression would strengthen the inhibition of IGFBP-4 degradation. This inhibition might be partly mediated by direct interaction of IGFBP-4 proteinase(s) and heparinbinding domain within the C-terminal region from IGFBP-3 and -5. (Endocrinology 140: [4175][4176][4177][4178][4179][4180][4181][4182][4183][4184] 1999) 
nective tissue growth factor (CTGF) and from proteins not related to IGFBP, heparan/heparin interacting protein (HIP) and vitronectin, but not from p36 subunit of annexin II tetramer, inhibited IGFBP-4 degradation. Furthermore, IGFBP-3, mutated on its heparin-binding domain, was not able to inhibit IGFBP-4 proteolytic degradation. So, in ovine preovulatory follicles, IGFBP-4 proteolytic degradation both 1) depends on IGFs, and 2) is inhibited by IGFBP-3 via its C-terminal heparin-binding domain as well as by heparin-binding domain containing peptides. These data suggest that in early atretic follicles, the increase in IGFBP-2 participates in the decrease in IGFBP-4 degradation. In late atretic follicles, the increase in the levels of C-terminal IGFBP-3 proteolytic fragments, generated by IGFBP-3 degradation, as well as the increase in IGFBP-5 expression would strengthen the inhibition of IGFBP-4 degradation. This inhibition might be partly mediated by direct interaction of IGFBP-4 proteinase(s) and heparinbinding domain within the C-terminal region from IGFBP-3 and -5. (Endocrinology 140: [4175] [4176] [4177] [4178] [4179] [4180] [4181] [4182] [4183] [4184] 1999) I NSULIN-LIKE GROWTH FACTOR binding protein (IGFBP)-4 proteolytic degradation has been reported in a wide variety of in vitro models, including sheep and human fibroblasts (1) (2) (3) (4) , nonsmall cell lung cancer cell lines (5), mouse (6) and human (7) osteoblasts, human decidual cells (8) , human endometrial stromal cells (9) , and rat granulosa cells (10) . In these models, IGFBP-4 degradation was shown to be IGF dependent. Particulary, IGFs have been shown to enhance IGFBP-4 degradation in a receptor-independent manner in conditioned media of human endometrial stromal cells (9) , human decidual cells (8) , and human fibroblasts (1) . Moreover, addition of IGFBP-3, -5, or -6 in MC3T3-E1 osteoblast-conditioned medium (6, 11) , addition of IGFBP-3 in human dermal fibroblast-conditioned medium (4), addition of IGFBP-1, -2, or -3 in human follicular fluid (12) , and addition of IGFBP-2, -3, -5, and -6 in rat granulosa cell-conditioned medium (10) led to an inhibition of IGFBP-4 degradation. The mechanism of IGF enhancement of IGFBP-4 proteolysis is unknown. In one hypothesis, it is proposed that a conformational change of IGFBP-4 upon binding to IGFs results in the enhancement of IGFBP-4 proteolytic degradation (8, 9) . In an alternative hypothesis, Fowlkes et al. suggested that free IGFBP-3, -5, and -6 are able to directly inhibit IGFBP-4 protease(s) in MC3T3-E1 cells-conditioned medium by binding at the level of their C-terminal heparin binding domain (6, 11) . In this latter model, saturation of IGFBP-3, -5, or -6 by IGFs would lead to the release and the activation of protease(s) responsible for IGFBP-4 degradation.
In vivo, in the sheep ovary, preovulatory follicles are characterized by a high IGF bioavailability, by high levels of IGFBP-3, likely coming from serum, and by a high IGFBP-4 proteolytic activity. In contrast, atretic follicles are characterized by a low IGF bioavailability, by a high increase in the expression of IGFBP-2 (early atresia) and -5 (late atresia), by an increase in IGFBP-3 proteolytic degradation (at least in small follicles), as well as by a low IGFBP-4 proteolytic activity (13) (14) (15) . So, in the sheep ovary, there is a positive relationship between IGF bioavailability and IGFBP-4 degradation on one hand, and a negative relationship between IGFBP-3 proteolytic degradation, IGFBP-2 and -5 expression and IGFBP-4 degradation on the other hand. In this work, we have investigated the implication of IGFs, IGFBP-2, IGFBP-3 and IGFBP-3 proteolytic fragments on IGFBP-4 proteolytic degradation in ovine preovulatory follicles.
Materials and Methods Materials
Fluorogestone acetate sponges used to synchronise estrous cycles and PMSG were obtained from Intervet (Angers, France [371] [372] [373] [374] [375] [376] [377] [378] [379] [380] [381] [382] [383] (NQNSRRPSRATWL), were kindly provided by Dr. K. T. Preissner (Bad Nauheim, Germany). Heparin (ammonium salt from porcine intestinal mucosa) and aprotinin were purchased from Sigma (L'Issle d'Abeau Chesnes, France). Heparin-Sepharose CL6B beads were obtained from Pharmacia & Upjohn (Uppsala, Sweden). EDTA was purchased from Prolabo (Fontenay-sousbois, France). Rabbit polyclonal antiserum against human IGFBP-2 was obtained from Dr. Schwander (Basel, Switzerland) and rabbit polyclonal antiserum against IGFBP-4 was purchased from Ubi (Lake Placid, NY). Mouse monoclonal antiserum against human IGFBP-3 was purchased from UCB (Braine L'Alleud, Belgium). Mouse monoclonal antibody against IGF-I was a gift from Dr. J. Closset (Liège, Belgium), and mouse monoclonal against IGF-II was obtained from Amano Pharmaceutical Co. (Nagoya, Japan). Antirabbit and antimouse IgG antibodies coupled to horseradish peroxidase were purchased respectively from Diagnostic Pasteur (Marnes la coquette, France) and DAKO Corp. (Trappes, France). Nitrocellulose membranes were purchased from Schleicher & Schuell, Inc. (Ecquevilly, France) and the enhanced chemiluminescence detection system for immunoblots was obtained from Amersham Pharmacia Biotech (Les Ulis, France).
Collection of follicular fluid
Adult Romanov or Ile-de-France ewes were treated with progestagen (intravaginal fluorogestone acetate sponges, 40 mg) for 15 days to synchronize estrus. They were injected with 40 mg of FSH or 500 UI of PMSG 24 h before the sponge removal. Twenty-four hours after sponge removal, the ovaries were collected by castration. Follicular fluids from 5-to 7-mm diameter follicles were aspirated by puncture and individually stored at Ϫ20 C. The follicles characterized by the presence of IGFBP-3 and by the absence of IGFBP-2, -4, and -5 were considered as preovulatory, whereas follicles characterized by high levels of IGFBP-2 or IGFBP-2, -4, and -5 were considered as, respectively, early or late atretic follicles, as previously described (13) (14) (15) Studies of In other experiments, to test the ability of exogenous IGF-I to enhance intrafollicular degradation of IGFBP-4, follicular fluids from preovulatory and atretic follicles were incubated with IGFBP-4 for 30 min (preovulatory and early atretic follicles) and for 2 h (late atretic follicles), in the presence or absence of IGF-I.
IGFBP-3 proteolytic degradation and fragments separation
Twenty micrograms of nonglycosylated human IGFBP-3 (E. coli) were incubated with 0.2 g plasmin (1:270 molar ratio) in 80 l 20 mm Tris-HCl, pH 7.5, 0.15 m NaCl for 45 min at 37 C. The reaction was stopped by addition of 0.5 mm final Tosyl-lysine chloromethylketone (TLCK). The fragments were separated as already described (20) . Briefly, the reaction mixture was diluted in 1:2 with 10% acetonitrile, 0.1% Trifluoro acetic acid (TFA), and loaded onto a C 8 RP 300 Aquapore Brownlee column. Peptides were eluted by 10 -40% acetonitrile linear gradient. Elution peaks monitored by absorbance at 210 nm were identified by microsequencing. The collected tubes were dried under vacuum and stored at Ϫ20 C. Peptides used within this study correspond to 1-95 and 161-264 IGFBP-3 fragments (21).
Binding of intrafollicular IGFBP-3 or recombinant IGFBP-3 to heparin-Sepharose beads
We incubated 2.5 l of follicular fluid from ovine preovulatory, early atretic or late atretic follicles in TBS/BSA with or without 10 l of heparin-Sepharose beads (2 mg/10 l in TBS) in the absence or presence of 200 ng IGF-I and/or 500 ng IGFBP-2 (final volume, 20 l). After an overnight incubation at 37 C, the samples were centrifuged for 1 min at 15,000 ϫ g. The pellets of heparin-Sepharose beads were rinced three times with TBS/BSA. We then added 10 l of Laemmli sample buffer to both the supernatants and pellets before WLB. 
IGFBP-4 proteolytic degradation by plasmin
To test the involvement of IGF-I in IGFBP-4 degradation by plasmin in vitro, 20 ng of IGFBP-4 were incubated in TBS/Tween 20 with 15 ng of plasmin, with or without IGF-I, for 5 min, 30 min, 2 h, or 5 h at 37 C (final volume, 10 l). The reaction was stopped by addition of Laemmli sample buffer. The samples were then submitted to WLB.
Western ligand blotting (WLB)
IGF-II was iodinated by the iodogen method and purified by Sephadex G-50 chromatography by using a 0.1 m ammonium acetate elution buffer. WLB was performed according to the method of Hossenlopp et al. 
Immunoblotting
After electrophoresis and electrotransfer of proteins, as described for WLB, nitrocellulose filters were treated for 2 h at room temperature with TBS containing 10% nonfat dry milk (NFDM) and 0.2% Tween-20 to saturate nonspecific sites. Thereafter, filters were incubated for 1 h at 37 C in TBS containing 5% NFDM, 0.05% Tween-20, and antibodies against IGFBP-2 (final dilution 1/1000), IGFBP3 (final dilution 1/2000) or IGFBP-4 (final dilution 1/1000). Once washed in TBS containing 1% NFDM and 0.2% Tween-20, nitrocellulose filters were incubated for 1h at 37 C with an antirabbit or antimouse IgG antibody coupled to horseradish peroxidase (final dilution 1/2000). After washing, the signal was revealed by chemiluminescence detection. Table 1 .
IGF-binding activity assay

Quantification of WLB
WLB was quantified by a phosphoimager (Storm/Image Quant, Molecular Dynamics, Inc.). Quantification was performed as previously described (15) . Briefly, the amount of radiolabeled IGF-II bound to each IGFBP was expressed as the integrated optical density (IOD) of the corresponding band, expressed in arbitrary units. The extent of IGFBP-4 degradation by follicular fluid was determined as the difference I -20 -I 37 
Statistical analysis
Data are presented as the mean Ϯ se. Statistical comparisons of means were performed by Student's t test. Comparisons with P Ͼ 0.05 were not considered significant.
Results
IGF-dependence of IGFBP-4 proteolytic degradation
As previously described (15) , incubation of 2 l of follicular fluid from preovulatory follicles with 15 ng or 20 ng of IGFBP-4 for 20 h at 37 C led to a complete disappearance of IGFBP-4 as assessed by WLB (Fig. 1A, lane 2 vs. 1) , and the generation of a 19-kDa fragment that failed to bind IGFs, detected by immunoblotting (Fig. 1B) . Preliminary kinetic experiments showed that in these conditions approximately 40% of IGFBP-4 was degraded after 30 min of incubation. Therefore, we tested the effect of exogenous IGF-I on IGFBP-4 degradation by incubating preovulatory follicles with IGFBP-4 and IGF-I for 1 h. In these conditions, addition of 200 ng of exogenous IGF-I led to an increase of IGFBP-4 degradation ( Fig. 2A; Fig. 2B , P Ͻ 0.01, n ϭ 10). When the same experiment was performed on early and late atretic follicles, IGF-I did not enhance IGFBP-4 degradation whatever the duration of incubation (data not shown, P Ͼ 0.3).
When incubation of follicular fluid from preovulatory follicles was performed during 20 h, addition of 20 ng of IGFBP-3, 160 ng of IGFBP-2, or 2 l of monoclonal antibodies against IGF-I and -II to the incubation medium led to the inhibition of IGFBP-4 proteolytic degradation ( Fig. 1A; Fig.  1B ; Fig. 3 , P Ͻ 0.05 for IGFBP-2, P Ͻ 0.01 for IGFBP-3 and monoclonal antibodies). The inhibitory effect of IGFBP-2 and IGFBP-3 on IGFBP-4 degradation was dose dependent (Fig.  4) . The inhibition of IGFBP-4 proteolysis by IGFBP-2 or -3 or by antibodies against IGF-I and -II was not a consequence of substrate competition with proteases. Indeed, in our conditions and as previously described, exogenous IGFBP-3 was 
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Specific IGF-binding activity was assayed as described in Materials and Methods. Experimental data are expressed as the mean Ϯ SE of three independent experiments, except for IGFBP-3mHBD (n ϭ 2).
only slightly, if at all degraded in ovine preovulatory follicles (15) (data not shown). IGFBP-2 was only slightly degraded in ovine preovulatory follicles as assessed by WLB and immunoblotting (data not shown). Furthermore, monoclonal antibodies against IGF-I and -II were not degraded in preovulatory follicular fluid, as assessed by immunoblotting (data not shown).
The addition of 200 ng of IGF-I totally reversed the inhibitory effects of IGFBP-2 and IGFBP-3 on IGFBP-4 degradation ( Fig. 1A; Fig. 3 : P Ͻ 0.05 for IGFBP-2, P Ͻ 0.01 for IGFBP-3). The addition of 200 ng of both IGF-I and IGF-II totally reversed the inhibitory effects of the monoclonal antibodies against IGF-I and -II on IGFBP-4 degradation as well ( Fig. 1A ; Fig. 3 , P Ͻ 0.01 for monoclonal antibodies). The reversion by IGF-I and -II of IGFBP-2 or -3-induced inhibition of IGFBP-4 degradation was dose dependent (Figs. 5 and 6 ). In the same conditions, LongR3-IGF-I led to a weak reversion of IGFBP-4 proteolysis (Fig. 6 ). All these results suggest a role of IGFs in the regulation of intrafollicular IGFBP-4 degradation.
Effects of IGFBP-3 N-and C-terminal proteolytic fragments and of synthetic peptides on intrafollicular IGFBP-4 proteolytic degradation
In the sheep ovary, IGFBP-4 proteolytic activity is maximal in preovulatory follicles containing only IGFBP-3, likely bound to IGFs. In contrast, IGFBP-4 proteolytic activity is minimal in atretic (particularly small) follicles, characterized by a high increase in IGFBP-2 and -5 expression, and by an increase in IGFBP-3 proteolytic degradation. Recently, Fowlkes et al. suggested that, in murine osteoblast cell line conditioned medium, IGFBP-3 and IGFBP-5 are able to inhibit IGFBP-4 degradation by directly interacting with protease(s) via their heparin-binding region (6, 11) . In ovine preovulatory follicles, we have tested if proteolytic fragments derived from IGFBP-3, as well as heparin-binding peptides derived from the C-terminal region of IGFBP-3 and -5, were able to inhibit IGFBP-4. The IGFBP-3 C-terminal, but not N-terminal domain, strongly inhibited IGFBP-4 proteolysis in a dose-dependent manner ( Fig. 7A; Fig. 7B , P Ͻ 0.01 for 62.7 ng of the C-terminal domain). Moreover, the synthetic peptides P3 and P5, corresponding to the IGFBP-3 and IGFBP-5 C-terminal heparin-binding domain inhibited IGFBP-4 proteolysis in a dose-dependent manner as well ( Fig. 8; Fig. 9 , P Ͻ 0.05 for 1 g). Heparin totally reversed the inhibitory effect of these peptides, whereas IGF-I and -II had no clear effect (Fig. 8) . In contrast, neither the basic amino acid-rich PA5 peptide, derived from IGFBP-5, that is not able to bind heparin (17) , nor P1 and P4 peptides derived from the C-terminal region of IGFBP-1 and IGFBP-4, respectively (both devoid of heparin-binding domain) were able to mimic the inhibition of IGFBP-4 proteolysis. Furthermore, among the different peptides derived from CTGF (IGFBP-related protein 2, see Materials and Methods), only CTGF [247] [248] [249] [250] [251] [252] [253] [254] [255] [256] [257] [258] [259] [260] , that binds heparin with high affinity (19) , was able to inhibit IGFBP-4 proteolytic degradation (Fig. 9) . Finally, heparinbinding domain-containing peptides derived from proteins not related to IGFBPs (HIP, p36 subunit of annexin II tetramer, vitronectin, see Materials and Methods) were studied for their ability to inhibit IGFBP-4 proteolytic degradation. The vitronectin derived peptide VN 357-370 only slightly inhibited IGFBP-4 proteolytic degradation. The VN 341-355 peptide (containing the consensus heparin binding domain XBBXBX) and the HIP peptide inhibited IGFBP-4 proteolysis in a dose-dependent manner (P Ͻ 0.05 for 10 g, and P Ͻ 0.01 for 6 g, respectively; Fig. 9 ). The heparin-binding domain containing peptide derived from the p36 subunit of annexin tetramer II had no effect. Overall, the order of magnitude of inhibition of IGFBP-4 degradation was P5 Ͼ P3 Ͼ 
Effects of IGFBP-3mHBD on intrafollicular IGFBP-4 proteolytic degradation
To assess whether the IGFBP-4 degradation induced by IGFBP-3 was mediated by the IGFBP-3 carboxy-terminal heparin-binding domain, we have tested the ability of a full-length IGFBP-3 protein mutated in the HBD region (IGFBP-3mHBD: 215 KNGFYHSRQCETSMDGEA 232) to inhibit the IGFBP-4 proteolytic degradation. IGFBP-3mHBD induced 13% of inhibition of IGFBP-4 proteolysis, whereas nonmutated IGFBP-3 induced 69% of inhibition (Fig. 10) . These results confirm the involvement of the IGFBP-3 heparin-binding domain in the inhibition of the IGFBP-4 proteolytic degradation induced by IGFBP-3.
Effects of IGF-I on the binding of IGFBP-3 to heparin
Addition of IGF-I had no effect on the binding of recombinant IGFBP-3 to the heparin-Sepharose beads (data not shown). Moreover, addition of IGF-I or IGFBP-2 to preovulatory follicles had no effect on the binding of endogenous IGFBP-3 (Fig. 11) . Finally, there was no difference in the ability of the native endogenous IGFBP-3 from preovulatory follicle in comparison with atretic follicles to bind heparin. Addition of IGF-I to early or late atretic follicles had no effect on the binding of endogenous IGFBP-3 to heparin-Sepharose beads (Fig. 11) .
Discussion
In the sheep, it has been previously shown that follicular growth is characterized by an increase in IGFBP-4 proteolytic degradation, a decrease in IGFBP-3 proteolytic degradation and IGFBP-2 expression, as well as an increase in IGF bioavailability (13) (14) (15) . In contrast, follicular atresia is characterized by a decrease in IGFBP-4 proteolytic degradation, an increase in IGFBP-3 proteolytic degradation and in IGFBP-2 (early atresia) and -5 (late atresia) expression, as well as a decrease in IGF bioavailability (13) (14) (15) . In the present work, several observations strongly suggest a role of IGFs in IGFBP-4 degradation. First, addition of IGF-I to follicular fluid from preovulatory follicles (but not from atretic follicles) accelerated IGFBP-4 degradation. Secondly, addition of IGFBP-2, -3, and monoclonal antibodies against IGF-I and IGF-II dose dependently inhibited IGFBP-4 degradation. This inhibition was dose dependently reversed by IGF-I and -II but poorly by LongR3-IGF-I. Similarly, Cwyfan Hughes et al. have recently shown that IGFBP-1, -2, and -3 inhibited IGFBP-4 degradation in human preovulatory follicles in vivo (12) . In several in vitro models as well, addition of IGFBP-2, -3, -5, and/or -6 inhibited IGFBP-4 degradation, an effect that was reversed by IGFs (4, 6, 10, 11) . All of these results suggest that in ovine growing follicles, the increase in IGF bioavailability participates in the increase in IGFBP-4 proteolytic degradation. In contrast, in degenerating follicles, the early and late increase in IGFBP-2 and IGFBP-5 expression, respectively, may be partly responsible for the decrease in IGFBP-4 proteolytic degradation.
Recently, Fowlkes et al. have shown that the C-terminal fragment of IGFBP-3, as well as peptides derived from the C-terminal heparin-binding domain of IGFBP-3, -5, or -6, are able to inhibit IGFBP-4 degradation in conditioned medium of murine bone cells (6, 11) . In the present work, we have tested whether heparin-binding domains from IGFBP-3 and -5 were able to inhibit the IGFBP-4-degrading protease(s) in ovine follicles. Firstly, the C-terminal, but not the N-terminal, IGFBP-3 fragment as well as peptides derived from the Cterminal heparin-binding domains from IGFBP-3 (P3) and -5 (P5) dose dependently inhibited IGFBP-4 proteolysis, this inhibition being not clearly reversed by IGFs. A heparinbinding peptide derived from CTGF (CTGF 247-260 ) also dose . Experimental data were expressed as the mean Ϯ SE of two to three independent experiments and on two to three follicles.
REGULATION OF IGFBP-4 PROTEOLYTIC DEGRADATION
dependently inhibited IGFBP-4 degradation. In the same way, heparin binding domain-containing peptides from HIP and vitronectin (VN 341-355 , VN 357-370 ), but not from p36 subunit of annexin II tetramer, were able to inhibit the IGFBP-4 degradation. The ability of these peptides to inhibit IGFBP-4 degradation was not strictly correlated with their ability to bind heparin. Indeed, the peptide derived from the p36 subunit of annexin II tetramer, although able to bind heparin with high affinity (23), was not able to inhibit IGFBP-4 degradation. Furthermore, the vitronectin VN 341-355 peptide was more efficient than VN 357-370 for inhibition of IGFBP-4 degradation, whereas the latter has a higher affinity for heparin than the former (24) . Overall, these data suggest some specificity in the inhibition of IGFBP-4 degradation by the IGFBP-3 and Ϫ5 C-terminal-containing heparin-binding domain. Interestingly, the P5 peptide, as well as the vitronectin peptide (VN [357] [358] [359] [360] [361] [362] [363] [364] [365] [366] [367] [368] [369] [370] ), were recently shown to directly modulate plasminogen activation to plasmin (24, 25) . Furthermore, IGFBP-3 was shown to bind plasminogen via its heparinbinding domain (26) . Finally, in ovine follicle, IGFBP-3 mu- Our results suggest two mechanisms of regulation of IGFBP-4 proteolytic degradation in ovine preovulatory follicles. Firstly, the IGF dependence is suggested by the fact that, in the presence of intrafollicular endogenous IGFBP-3 (likely complexed to endogenous ALS and IGF-I) and exogenous added IGFBP-4, IGF-I enhances, whereas monoclonal antibodies against IGF-I and -II inhibit IGFBP-4 degradation. In these conditions, IGF dependence may be due to conformational changes of IGFBP-4 upon binding to its ligand allowing the protease to acceed to the cleavage site, as suggest by others (8, 9, 27) . Arguing against this hypothesis is the fact that, in our in vitro conditions, IGFBP-4 proteolytic degradation by plasmin was not enhanced by the addition of IGF-I (data not shown). One can note that the intensity of IGF-enhancement of IGFBP-4 degradation in follicular fluid is low (54.5% of degradation vs. 40% without exogenous IGF-I, and only 10% of inhibition of degradation with monoclonal antibodies) in comparison with similar in vitro experiments (Ͼ90% of degradation of IGFBP-4 after addition of IGF-I (3, 7) and is observed only by incubating follicular fluid with IGFBP-4 during 30 min. This is likely due to the fact that in preovulatory follicles, levels of endogenous IGFs (approximately 1 g/ml of both IGF-I and -II) as well as the IGFs/IGFBPs ratio are much higher than in most conditioned-cell culture medium in vitro. We suspect that this relatively large excess in endogenous IGFs could "mask" the effect of exogenous added IGFs. Secondly, the inhibition of IGFBP-4 degradation by IGFBP-heparin-binding domains is supported by the strong inhibition of IGFBP-4 proteolytic degradation by the IGFBP-3 C-terminal proteolytic fragment Anyway, addition of exogenous IGFBP-3 to preovulatory follicular fluid is only experimental because such an increase in levels of intrafollicular free IGFBP-3 does not occur in vivo and is not representative of a role of intrafollicular endogenous IGFBP-3 on IGFBP-4 degradation. In particular, we have shown that there was no difference in the ability of endogenous (native) IGFBP-3 from healthy preovulatory follicles in comparison with atretic follicles (characterized by high levels of IGFBP-2 and -5 and low IGF bioavailability) to bind to heparin-Sepharose beads. Furthermore, Cwyfan Hughes et al. (29) have shown by chromatography that in human atretic follicles, there was no more IGFBP-3 within the small (likely IGF-free) complex, susceptible to interact with IGFBP-4 protease, compared with dominant follicles, suggesting that endogenous native IGFBP-3 does not play a major role in the modulation of IGFBP-4 degradation in vivo. Moreover, the inhibition of IGFBP-4 degradation by IGFBP-2 may be due to both sequestration of IGFs and direct interaction with protease. In particular, IGFBP-2 has been shown to bind heparin, although further studies are needed to identify its heparin-binding domain (17, 28, 30) . One may hypothesize that the lesser efficiency of IGFBP-2 to inhibit IGFBP-4 degradation, in comparison with IGFBP-3, is partly due to its lower affinity to heparin (17) .
Finally, as an alternative hypothesis to explain the IGF dependence of IGFBP-4 degradation, Conover et al. (3) proposed that IGFs would directly activate IGFBP-4 proteinase(s). Of note is the recent cloning of a protein called L56 protease, containing an IGFBP-related N-terminal domain and a C-terminal domain related to serine proteases (31) (32) (33) . Experiments are necessary to test the ability of IGFs to modulate the activity of L56 protease.
IGF-I and IGF-II have been shown to play a pivotal role in proliferation and differentiation of granulosa cells, synergizing with gonadotropins (34, 35) . Moreover, IGFBP-4 has been shown to inhibit IGF action in a variety of tissues (36 -38) . In particular, protease-resistant but not -sensitive form of IGFBP-4 inhibits IGF actions (39 -41) . In the ovary, it has been shown that IGFBP-4, but not IGFBP-4 proteolytic fragments, inhibits IGF-I-induced oestradiol production by human granulosa cells in vitro (42, 43) . So, changes in intrafollicular IGFBP-4 levels during growth and atresia of ovarian follicles might participate in the change in intrafollicular IGF-bioavailability, as suggested by in vitro experiments (13) .
In conclusion, we have shown that in vivo, particularly in ovine ovarian follicles, IGFBP-4 proteolytic degradation is both IGF-dependent and inhibited by IGFBP-3 C-terminal domain as well as by heparin-binding domain-containing peptides. These data suggest that in early atretic follicles, the increase in IGFBP-2 expression participates in the decrease in IGFBP-4 degradation, the mechanism remaining to be elucidated. Furthermore, in late atretic follicles, the increase in the levels of C-terminal IGFBP-3 proteolytic fragments, generated by IGFBP-3 degradation, as well as the increase in IGFBP-5 expression, would strengthen the inhibition of IGFBP-4 degradation. This inhibition might be partly mediated by direct interaction of the heparin-binding domain within the C-terminal region from IGFBP-3 and -5 with IGFBP-4 proteinase(s) . FIG. 11 . Binding of intrafollicular IGFBP-3 to heparin-Sepharose beads. We incubated 2.5 l of follicular fluid from ovine preovulatory, early atretic, or late atretic follicles with heparin-Sepharose beads with or without 200 ng of IGF-I and 500 ng of IGFBP-2 in a final volume of 20 l. After an overnight incubation at 37 C, the samples were centrifuged for 1 min at 15,000 ϫ g. Then, pellets and supernatants were submitted to WLB as described in Materials and Methods. Experimental data are expressed as the mean Ϯ SE of five to six independent experiments and on five to six follicles. Means were not significantly different.
